Positive Results Move Anemia Contender Enarodustat Towards First Filing
Executive Summary
Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.
You may also be interested in...
First Approval For AZ's Roxadustat With China Green Light
China is the first country to give the green light to roxadustat, AstraZeneca and FibroGen's first-in-class oral inhibitor of HIF-PHI, which could become standard of care to treat anemia in chronic kidney disease patients.
Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh
Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.